Skip to content
Back to glossary
Therapeutics

Semaglutide

DESemaglutid

Semaglutide is a long-acting GLP-1 receptor agonist. It is approved for type 2 diabetes (as Ozempic and Rybelsus). It is also approved for chronic weight management (as Wegovy). One landmark trial stands out. The SELECT trial showed a 20% drop in major cardiovascular events. That was in adults with obesity and existing heart disease, even without diabetes. Its longevity-relevant effects include sustained weight loss and better insulin sensitivity. It also lowers inflammation and may protect the brain and kidneys. But if you use it purely to extend lifespan as a healthy adult, that is experimental and not endorsed.

Last reviewed:

This definition is educational and is not medical advice, a diagnosis, or treatment. Talk to a doctor about any health decisions. Read our full medical disclaimer

Sources

  1. Lincoff AM, Brown-Frandsen K, Colhoun HM et al.. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). *New England Journal of Medicine*doi:10.1056/NEJMoa2307563

Related studies from the research library